Search

Sloan Kettering Institute Director Thomas J. Kelly is the co-recipient of the 2010 Louisa Gross Horwitz Prize from Columbia University.

… Friday, April 1, 2011 Summary Sloan Kettering Institute Director Thomas J. Kelly is the co-recipient of the 2010 Louisa Gross Horwitz Prize from Columbia University. Sloan Kettering Institute Director Thomas J. Kelly is the co-recipient of the 2010 Louisa Gross Horwitz Prize from Columbia University.

Neratinib, which targets mutations that drive cancer growth, is showing promise for treating several types of cancer.

… Sunday, April 2, 2017 Summary Neratinib,  an experimental drug developed to target certain mutations that drive cancer growth, is showing promise for treating several types of cancer. The findings from a phase II study were presented at the 2017 AACR Annual Meeting . Highlights Basket trials are based

New findings could lead to a different kind of cancer drug that targets a DNA damage repair pathway called nucleotide excision repair.

… Monday, January 11, 2021 Summary A study has uncovered new findings about a DNA repair pathway called nucleotide excision repair and its role in the development of cancer. The paper also details how this defective pathway could be targeted with drugs. Memorial Sloan Kettering scientists have discovered

Learn more about DeepHeme, an artificial intelligence tool that helps doctors to diagnose blood and bone marrow cancers.

… Wednesday, June 11, 2025 Researchers at Memorial Sloan Kettering Cancer Center (MSK), the University of California, San Francisco (UCSF), and University of California, Berkeley (UC Berkeley) have developed an artificial intelligence (AI) tool called DeepHeme that can help automate the diagnosis of blood

Researchers have found that more than 20% of people with a type of cancer called advanced non-clear cell renal cell carcinoma have disease that is driven by inherited cancer mutations.

… Thursday, September 6, 2018 Summary Research conducted at MSK has shown that more than 20% of people with a type of kidney cancer called advanced non-clear cell renal cell carcinoma have disease that is driven by inherited cancer mutations. This number is much higher than expected. Kidney cancer , also

The global clinical research community is facing a clear imperative to move beyond traditional manual data management methods in order to improve data capture, integrity, and exchange, while pursuing other related efficiencies.

… Tuesday, January 14, 2025 The global clinical research community is facing a clear imperative to move beyond traditional manual data management methods in order to improve data capture, integrity, and exchange, while pursuing other related efficiencies. Memorial Sloan Kettering Cancer Center (MSK) has

Vivian Strong, MD, FACS, the Iris Cantor Chair, addressed colleagues and gastric cancer experts from around the world at the International Gastric Cancer Congress 2022.

… Wednesday, March 30, 2022 Vivian Strong, MD, FACS , the Iris Cantor Chair, addressed colleagues and gastric cancer experts from around the world at the International Gastric Cancer Congress 2022 . Dr. Strong presented “Highlights of What is New in Surgery for Gastric Cancer” as part of the meeting’s

Zvi Fuks has been elected a member of the Institute of Medicine, one of the highest honors in the fields of health and medicine.

… Saturday, January 1, 2011 Summary Zvi Fuks has been elected a member of the Institute of Medicine, one of the highest honors in the fields of health and medicine. Zvi Fuks has been elected a member of the Institute of Medicine (IOM), one of the highest honors in the fields of health and medicine. Dr.

In taking a new approach to finding treatments for hepatocellular carcinoma, MSK scientists have uncovered a potential drug target for this highly aggressive cancer.

… Tuesday, September 30, 2014 Summary In taking a new approach to finding treatments for hepatocellular carcinoma, MSK scientists have uncovered a potential drug target for this highly aggressive cancer. Increasingly, scientists are findings ways to shortcut the search for new cancer therapies. In a recent

A new imaging approach relying on Cerenkov light could sometimes substitute for PET scans and improve diagnostic services in underserved areas.

… Monday, April 11, 2022 Positron emission tomography (PET) is one of the most widely used diagnostic tools in cancer care. PET scans show the location of a tumor, usually based on increased glucose intake, a hallmark of cancer cells. Despite their effectiveness, PET scans can be hard to access in developing